Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: February 25th, 2010 - February 25th, 2011

Target Audience
This activity was developed for physicians, pharmacists, and other healthcare professionals practicing in a managed care environment.

Learning Objectives
At the completion of this activity participants should be able to:

  • Identify practical, strategic management skills needed to utilize evidence-based standards for specialty benefit strategies that succeed in a value-based healthcare environment
  • Discuss the principles of evidence-based medicine driving drug utilization appropriate to biopharmaceuticals, with an emphasis on recent clinical and pharmacoeconomic studies, as well as emerging therapies
  • Identify specific avenues for attaining value, by balancing cost, quality, and access rather than by simple cost-minimization policies that produce negative quality and/or access results
  • Identify how the early recognition and treatment of multiple sclerosis can modify the course/progression of the disease and reduce future economic costs
  • Evaluate outcomes criteria for measuring drug performance beyond the empirical abatement of symptoms, including early treatment, disease modification, decreased hospitalization, prevention of other disease states, improved cognitive function, and quality of life and worker productivity

Estimated time to complete this activity: 1.0 hour

Physician Credit Designation
The University of Cincinnati designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Pharmacists Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-10-054-H01-P.

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker's bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The University of Cincinnati, the associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.

Faculty Disclosures
Thomas Bramley, RPh, PhD, is an employee of Xcenda, a pharmaceutical consulting firm that works with a variety of pharmaceutical companies. He does not intend to discuss any non-FDA-approved or investigational use of any product/device.

Jack Burks, MD, is on the Advisory Board of Bayer, Biogen/Idec, and Lilly. He is a consultant to Lilly and Wyeth. He intends to discuss either non-FDA-approved or investigational drugs for multiple sclerosis.

Elizabeth Mauer, PharmD, MBA, is a consultant to Abbott. She does not intend to discuss any non-FDA-approved or investigational use of any product/device.

Robert Navarro, PharmD, is a consultant to Daiichi Sankyo, Novo Nordisk, and Purdue Frederick Co. He does not intend to discuss any non-FDA-approved or investigational use of any product/device.

*Content will include non-FDA-approved uses.

The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Trade names used in this supplement are for the learner's reference only. No promotion of or bias toward any product should be inferred

Last modified: March 21, 2014